Free Trial

Pieris Pharmaceuticals Q3 2023 Earnings Report

Pieris Pharmaceuticals EPS Results

Actual EPS
-$8.80
Consensus EPS
-$8.80
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Pieris Pharmaceuticals Revenue Results

Actual Revenue
$19.52 million
Expected Revenue
$7.74 million
Beat/Miss
Beat by +$11.78 million
YoY Revenue Growth
N/A

Pieris Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

Pieris Pharmaceuticals Earnings Headlines

Palvella Therapeutics Inc (PVLA)
Elon Tax Shock?
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
One new option listing and one option delisting on December 16th
See More Pieris Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pieris Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pieris Pharmaceuticals and other key companies, straight to your email.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals (NASDAQ:PIRS), a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

View Pieris Pharmaceuticals Profile

More Earnings Resources from MarketBeat